Lisdexamfetamine Dimesylate In ADHD Phase 3 Data Presented

Armen Hareyan's picture
Advertisement

Shire plc and its collaborative partner New River Pharmaceuticals Inc. announced today that their investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX), yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years who received six months of treatment in an open-label phase III study. Results also demonstrated that at 6 months, 95 percent of children taking lisdexamfetamine dimesylate (NRP104/LDX) produced a "much improved" or "very much improved" rating on the Clinical Global Impressions

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement